{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:27:39Z","timestamp":1789230459875,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University Hospitals Cleveland, Pathology Departmental Research Program","award":["Grant 20233-R"],"award-info":[{"award-number":["Grant 20233-R"]}]},{"name":"University Hospitals Cleveland, Pathology Departmental Research Program","award":["Grant 20233-R"],"award-info":[{"award-number":["Grant 20233-R"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We studied transcription factors and hormones expressed by duodenal neuroendocrine cells in a consecutively diagnosed series of 53 patients with well-differentiated duodenal NETs. There were 30 men; the mean age was 65\u00a0years (33 to 81). The study included biopsies (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200918), endoscopic mucosal resections (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200919), and surgical resections (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200916). Three patients had multifocal disease; two had MEN1. Two patients had neurofibromatosis. Metastases were identified in 15\/23 patients with biopsied lymph nodes. PAX6 was expressed in 85%, followed by CDX2 in 65%; ARX was expressed in 33%, and no tumors expressed PAX4. The commonest hormone expressed was gastrin; 23 (43%) had diffuse expression, and 12 (23%) had focal reactivity. Pancreatic polypeptide was diffuse and strong in 17 tumors (32%) classified as PP cell NETs; another 3 tumors had focal staining (total\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920, 38%). Serotonin was identified only focally in 14 tumors (26%). Somatostatin was positive in 13 tumors (25%), 3 classical D cell tumors and 10 tumors with focal positivity. PYY was expressed in 10 tumors (19%), diffusely in 1 and focally in 9. CCK was identified in 6 tumors (11%), diffusely in 1 and focally in 5. Staining for glucagon\/GLPs, insulin, and motilin was completely negative in all tumors. Thirty tumors (57%) expressed more than one hormone; gastrin was the most frequent. In 2 composite gangliocytoma\/NETs (CoGNETs), the NET component expressed PP, and both NET and ganglion cells expressed ARX. These data identify a broad spectrum of duodenal NETs including novel cell types and a high incidence of plurihormonality.\n                  <\/jats:p>","DOI":"10.1007\/s12022-025-09868-x","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T23:48:27Z","timestamp":1750722507000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Extended Hormone Profiling Identifies a Wider Network of Duodenal Neuroendocrine Tumor Subtypes"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8008-6128","authenticated-orcid":false,"given":"Luvy","family":"Delfin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0715-6898","authenticated-orcid":false,"given":"Shereen","family":"Ezzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8418-5054","authenticated-orcid":false,"given":"Sylvia L.","family":"Asa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"9868_CR1","first-page":"21","volume":"3","author":"S van Noorden","year":"1980","unstructured":"van Noorden S, Falkmer S. Gut-islet endocrinology - some evolutionary aspects. Invest Cell Pathol 1980; 3:21-35.","journal-title":"Invest Cell Pathol"},{"key":"9868_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ctrv.2016.05.003","volume":"47","author":"S Singh","year":"2016","unstructured":"Singh S, Asa SL, Dey C et al. Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. Cancer Treat Rev 2016; 47:32-45.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"9868_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/his.13943","volume":"76","author":"AM Bellizzi","year":"2020","unstructured":"Bellizzi AM. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas. Histopathology 2020; 76(2):251-264.","journal-title":"Histopathology"},{"issue":"4","key":"9868_CR4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/his.14012","volume":"76","author":"D Hoskoppal","year":"2020","unstructured":"Hoskoppal D, Epstein JI, Gown AM et al. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours. Histopathology 2020; 76(4):550-559.","journal-title":"Histopathology"},{"issue":"4","key":"9868_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s12022-021-09684-z","volume":"32","author":"SL Asa","year":"2021","unstructured":"Asa SL, Arkun K, Tischler AS et al. Middle Ear \"Adenoma\": a Neuroendocrine Tumor with Predominant L Cell Differentiation. Endocr Pathol 2021; 32(4):433-441.","journal-title":"Endocr Pathol"},{"issue":"4","key":"9868_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/PAS.0000000000002009","volume":"47","author":"SL Asa","year":"2023","unstructured":"Asa SL, Mete O, Schuller U, Ramani B, Mirchia K, Perry A. Cauda Equina Neuroendocrine Tumors: Distinct Epithelial Neuroendocrine Neoplasms of Spinal Origin. Am J Surg Pathol 2023; 47(4):469-475.","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"9868_CR7","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/s41379-021-00820-y","volume":"34","author":"SL Asa","year":"2021","unstructured":"Asa SL, Mete O, Cusimano MD et al. Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. Mod Pathol 2021; 34(9):1634-1650.","journal-title":"Mod Pathol"},{"issue":"7","key":"9868_CR8","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1097\/PAS.0b013e3182819f0f","volume":"37","author":"SH Lee","year":"2013","unstructured":"Lee SH, Kim BC, Chang HJ et al. Rectal neuroendocrine and L-cell tumors: diagnostic dilemma and therapeutic strategy. Am J Surg Pathol 2013; 37(7):1044-1052.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"9868_CR9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.4143\/crt.2014.238","volume":"47","author":"JH Sohn","year":"2015","unstructured":"Sohn JH, Cho MY, Park Y et al. Prognostic Significance of Defining L-Cell Type on the Biologic Behavior of Rectal Neuroendocrine Tumors in Relation with Pathological Parameters. Cancer Res Treat 2015; 47(4):813-822.","journal-title":"Cancer Res Treat"},{"issue":"5","key":"9868_CR10","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/PAS.0000000000000400","volume":"39","author":"JY Kim","year":"2015","unstructured":"Kim JY, Kim KS, Kim KJ et al. Non-L-cell immunophenotype and large tumor size in rectal neuroendocrine tumors are associated with aggressive clinical behavior and worse prognosis. Am J Surg Pathol 2015; 39(5):632-643.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"9868_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12022-024-09813-4","volume":"35","author":"O Mete","year":"2024","unstructured":"Mete O, Dodington DW, Shen DL, Asa SL. The Clinicopathological Significance of Tumor Cell Subtyping in Appendiceal Neuroendocrine Tumors: A Series of 135 Tumors. Endocr Pathol 2024; 35(2):107-112.","journal-title":"Endocr Pathol"},{"issue":"11","key":"9868_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100595","volume":"37","author":"E Moser","year":"2024","unstructured":"Moser E, Ura A, Vogel L et al. ARX, PDX1, ISL1, and CDX2 Expression Distinguishes 5 Subgroups of Pancreatic Neuroendocrine Tumors With Correlations to Histology, Hormone Expression, and Outcome. Mod Pathol 2024; 37(11):100595.","journal-title":"Mod Pathol"},{"issue":"2","key":"9868_CR13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000444803","volume":"104","author":"A Vanoli","year":"2017","unstructured":"Vanoli A, La Rosa S, Klersy C et al. Four Neuroendocrine Tumor Types and Neuroendocrine Carcinoma of the Duodenum: Analysis of 203 Cases. Neuroendocrinology 2017; 104(2):112-125.","journal-title":"Neuroendocrinology"},{"issue":"2","key":"9868_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00428-011-1118-6","volume":"459","author":"G Hermann","year":"2011","unstructured":"Hermann G, Konukiewitz B, Schmitt A, Perren A, Kloppel G. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2. Virchows Arch 2011; 459(2):147-154.","journal-title":"Virchows Arch"},{"issue":"3","key":"9868_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00428-015-1890-9","volume":"468","author":"MJ Rosentraeger","year":"2016","unstructured":"Rosentraeger MJ, Garbrecht N, Anlauf M et al. Syndromic versus non-syndromic sporadic gastrin-producing neuroendocrine tumors of the duodenum: comparison of pathological features and biological behavior. Virchows Arch 2016; 468(3):277-287.","journal-title":"Virchows Arch"},{"issue":"6","key":"9868_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/PAS.0000000000001234","volume":"43","author":"A Vanoli","year":"2019","unstructured":"Vanoli A, Albarello L, Uncini S et al. Neuroendocrine Tumors (NETs) of the Minor Papilla\/Ampulla: Analysis of 16 Cases Underlines Homology With Major Ampulla NETs and Differences From Extra-Ampullary Duodenal NETs. Am J Surg Pathol 2019; 43(6):725-736.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"9868_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12022-022-09705-5","volume":"33","author":"V Nose","year":"2022","unstructured":"Nose V, Gill A, Teijeiro JMC, Perren A, Erickson L. Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes. Endocr Pathol 2022; 33(1):197-227.","journal-title":"Endocr Pathol"},{"issue":"1","key":"9868_CR18","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1677\/ERC-07-0157","volume":"15","author":"N Garbrecht","year":"2008","unstructured":"Garbrecht N, Anlauf M, Schmitt A et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 2008; 15(1):229-241.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"9868_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3904\/kjim.2011.26.1.103","volume":"26","author":"JA Kim","year":"2011","unstructured":"Kim JA, Choi WH, Kim CN, Moon YS, Chang SH, Lee HR. Duodenal somatostatinoma: a case report and review. Korean J Intern Med 2011; 26(1):103-107.","journal-title":"Korean J Intern Med"},{"issue":"1","key":"9868_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 2022; 33(1):115-154.","journal-title":"Endocr Pathol"},{"key":"9868_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3389\/fonc.2018.00291","volume":"8","author":"Y Okubo","year":"2018","unstructured":"Okubo Y, Yoshioka E, Suzuki M et al. Diagnosis, Pathological Findings, and Clinical Management of Gangliocytic Paraganglioma: A Systematic Review. Front Oncol 2018; 8:291.","journal-title":"Front Oncol"},{"issue":"4","key":"9868_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s12022-023-09762-4","volume":"34","author":"SL Asa","year":"2023","unstructured":"Asa SL, Uccella S, Tischler A. The Unique Importance of Differentiation and Function in Endocrine Neoplasia. Endocr Pathol 2023; 34(4):382-392.","journal-title":"Endocr Pathol"},{"key":"9868_CR23","doi-asserted-by":"crossref","unstructured":"Asa SL, Mohamed A. Pancreatic and Ileal Neuroendocrine Tumors: Metastatic Disease or a Novel MEN Syndrome? Am J Surg Pathol 2024.","DOI":"10.1097\/PAS.0000000000002290"},{"issue":"1","key":"9868_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0925-4773(99)00324-X","volume":"92","author":"C Dohrmann","year":"2000","unstructured":"Dohrmann C, Gruss P, Lemaire L. Pax genes and the differentiation of hormone-producing endocrine cells in the pancreas. Mech Dev 2000; 92(1):47-54.","journal-title":"Mech Dev"},{"issue":"2","key":"9868_CR25","doi-asserted-by":"publisher","first-page":"R103","DOI":"10.1530\/JME-14-0290","volume":"54","author":"T van der Meulen","year":"2015","unstructured":"van der Meulen T, Huising MO. Role of transcription factors in the transdifferentiation of pancreatic islet cells. J Mol Endocrinol 2015; 54(2):R103-R117.","journal-title":"J Mol Endocrinol"},{"issue":"2","key":"9868_CR26","first-page":"141","volume":"41","author":"K Watanabe","year":"1995","unstructured":"Watanabe K, Hasegawa H, Sakuma H, Tsuboi M, Ito S, Suzuki T. Two cases of duodenal gangliocytic paraganglioma: immunocytochemical characteristics. Fukushima J Med Sci 1995; 41(2):141-152.","journal-title":"Fukushima J Med Sci"},{"key":"9868_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2024.105695","volume":"154","author":"F Lutz","year":"2024","unstructured":"Lutz F, Hornburg SM, Moller K et al. PAX6 is a useful marker for pancreatic origin of neuroendocrine neoplasms: A tissue microarray study evaluating more than 19,000 tumors from 150 different tumor types. Hum Pathol 2024; 154:105695.","journal-title":"Hum Pathol"},{"issue":"1\u20132","key":"9868_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0925-4773(98)00182-8","volume":"79","author":"LI Larsson","year":"1998","unstructured":"Larsson LI, St-Onge L, Hougaard DM, Sosa-Pineda B, Gruss P. Pax 4 and 6 regulate gastrointestinal endocrine cell development. Mech Dev 1998; 79(1-2):153-159.","journal-title":"Mech Dev"},{"issue":"1","key":"9868_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ydbio.2012.02.024","volume":"365","author":"A Du","year":"2012","unstructured":"Du A, McCracken KW, Walp ER et al. Arx is required for normal enteroendocrine cell development in mice and humans. Dev Biol 2012; 365(1):175-188.","journal-title":"Dev Biol"},{"issue":"5","key":"9868_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036449","volume":"7","author":"A Beucher","year":"2012","unstructured":"Beucher A, Gjernes E, Collin C et al. The homeodomain-containing transcription factors Arx and Pax4 control enteroendocrine subtype specification in mice. PLoS ONE 2012; 7(5):e36449.","journal-title":"PLoS ONE"},{"issue":"4","key":"9868_CR31","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/dc.24368","volume":"48","author":"WM Hackeng","year":"2020","unstructured":"Hackeng WM, Morsink FHM, Moons LMG et al. Assessment of ARX expression, a novel biomarker for metastatic risk in pancreatic neuroendocrine tumors, in endoscopic ultrasound fine-needle aspiration. Diagn Cytopathol 2020; 48(4):308-315.","journal-title":"Diagn Cytopathol"},{"issue":"2","key":"9868_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12022-020-09611-8","volume":"31","author":"WM Hackeng","year":"2020","unstructured":"Hackeng WM, Schelhaas W, Morsink FHM et al. Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas. Endocr Pathol 2020; 31(2):108-118.","journal-title":"Endocr Pathol"},{"key":"9868_CR33","doi-asserted-by":"crossref","unstructured":"Ciobanu OA, Martin SC, Herlea V, Fica S. Insights into Epigenetic Changes Related to Genetic Variants and Cells-of-Origin of Pancreatic Neuroendocrine Tumors: An Algorithm for Practical Workup. Cancers (Basel) 2022; 14(18).","DOI":"10.3390\/cancers14184444"},{"issue":"5","key":"9868_CR34","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/gutjnl-2020-322595","volume":"71","author":"WM Hackeng","year":"2022","unstructured":"Hackeng WM, Brosens LAA, Kim JY et al. Non-functional pancreatic neuroendocrine tumours: ATRX\/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX\/PDX1 expression and tumour size. Gut 2022; 71(5):961-973.","journal-title":"Gut"},{"issue":"4","key":"9868_CR35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s12022-024-09826-z","volume":"35","author":"P Mattiolo","year":"2024","unstructured":"Mattiolo P, Bevere M, Mafficini A et al. Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX\/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres). Endocr Pathol 2024; 35(4):354-361.","journal-title":"Endocr Pathol"},{"issue":"5","key":"9868_CR36","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/PAS.0b013e31824aba59","volume":"36","author":"ES Chan","year":"2012","unstructured":"Chan ES, Alexander J, Swanson PE, Jain D, Yeh MM. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms. Am J Surg Pathol 2012; 36(5):737-743.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"9868_CR37","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1677\/ERC-08-0204","volume":"16","author":"V Fendrich","year":"2009","unstructured":"Fendrich V, Ramerth R, Waldmann J et al. Sonic hedgehog and pancreatic-duodenal homeobox 1 expression distinguish between duodenal and pancreatic gastrinomas. Endocr Relat Cancer 2009; 16(2):613-622.","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"9868_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.17116\/patol20198105111","volume":"81","author":"LE Gurevich","year":"2019","unstructured":"Gurevich LE, Proshchina AE, Voronkova IA, Ashevskaya VE, Korosteleva PA, Dolzhansky OV. [Differential diagnostic value of the expression of the transcription factor PDX-1 in neuroendocrine and non-neuroendocrine tumors of the pancreas and other organs]. Arkh Patol 2019; 81(5):11-21.","journal-title":"Arkh Patol"},{"key":"9868_CR39","doi-asserted-by":"crossref","unstructured":"Yang MX, Coates RF, Ambaye A et al. NKX2.2, PDX-1 and CDX-2 as potential biomarkers to differentiate well-differentiated neuroendocrine tumors. Biomark Res 2018; 6:15.","DOI":"10.1186\/s40364-018-0129-8"},{"issue":"7","key":"9868_CR40","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/PAS.0000000000000876","volume":"41","author":"Z Yang","year":"2017","unstructured":"Yang Z, Klimstra DS, Hruban RH, Tang LH. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver. Am J Surg Pathol 2017; 41(7):915-922.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"9868_CR41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00428-011-1118-6","volume":"459","author":"G Hermann","year":"2011","unstructured":"Hermann G, Konukiewitz B, Schmitt A, Perren A, Kloppel G. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2. Virchows Arch 2011; 459(2):147-154.","journal-title":"Virchows Arch"},{"issue":"7","key":"9868_CR42","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1177\/10668969231157319","volume":"31","author":"Y Xiang","year":"2023","unstructured":"Xiang Y, Malik F, Zhang PJ. Islet-1 Is Differentially Expressed Among Neuroendocrine and Non-Neuroendocrine Tumors and Its Potential Diagnostic Implication. Int J Surg Pathol 2023; 31(7):1294-1301.","journal-title":"Int J Surg Pathol"},{"issue":"4","key":"9868_CR43","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/MPA.0000000000000082","volume":"43","author":"JE Maxwell","year":"2014","unstructured":"Maxwell JE, O'Dorisio TM, Bellizzi AM, Howe JR. Elevated pancreatic polypeptide levels in pancreatic neuroendocrine tumors and diabetes mellitus: causation or association? Pancreas 2014; 43(4):651-656.","journal-title":"Pancreas"},{"key":"9868_CR44","unstructured":"Vinik A, Feliberti E, Perry RR. Pancreatic Polypeptide (PPoma). 2000."},{"key":"9868_CR45","first-page":"129","volume":"57","author":"T Tomita","year":"1986","unstructured":"Tomita T, Friesen SR, Kimmel JR. Pancreatic polypeptide-secreting islet cell tumor. A follow-up report. Cancer 1986; 57:129-133.","journal-title":"A follow-up report. Cancer"},{"key":"9868_CR46","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1056\/NEJM198607313150504","volume":"315","author":"TE Adrian","year":"1986","unstructured":"Adrian TE, Uttenthal LO, Williams SJ, Bloom SR. Secretion of pancreatic polypeptide in patients with pancreatic endocrine tumors. N Engl J Med 1986; 315:287-291.","journal-title":"N Engl J Med"},{"key":"9868_CR47","first-page":"117","volume-title":"Contemporary issues in gastroenterology","author":"TM O'Dorisio","year":"1985","unstructured":"O'Dorisio TM, Vinik AI. Pancreatic polypeptide and mixed peptide producing tumors of the gastrointestinal tract. In: Cohen S, Soloway RD, editors. Contemporary issues in gastroenterology. London: Churchill-Livingston, 1985: 117-128."},{"key":"9868_CR48","doi-asserted-by":"crossref","unstructured":"Tomita T, Friesen SR, Kimmel JR, Doull V, Pollock HG. Pancreatic polypeptide-secreting islet-cell tumors. A study of three cases. Am J Pathol 1983; 113:134\u2013142.","DOI":"10.1016\/0167-0115(83)90901-1"},{"key":"9868_CR49","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3109\/00365527809181786","volume":"13","author":"G Lundqvist","year":"1978","unstructured":"Lundqvist G, Krause U, Larsson L-I et al. A pancreatic-polypeptide-producing tumor associated with the WDHA syndrome. Scand J Gastroenterol 1978; 13:715-718.","journal-title":"Scand J Gastroenterol"},{"key":"9868_CR50","doi-asserted-by":"crossref","unstructured":"Mete O, Ezzat S, Perry A et al. The Pangenomic Classification of Pituitary Neuroendocrine Tumors: Quality Histopathology is Required for Accurate Translational Research. Endocr Pathol 2021.\u00a0","DOI":"10.1007\/s12022-021-09671-4"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09868-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-025-09868-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09868-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:01:32Z","timestamp":1768248092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-025-09868-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9868"],"URL":"https:\/\/doi.org\/10.1007\/s12022-025-09868-x","relation":{},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"15 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"University Hospitals Cleveland STUDY20221006.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}